

Supplementary Table S1. Association of *IDO* expression levels, at baseline, with HNSCC patients' clinicopathological data

Variable	No. patients	Mean \pm SD ^a	Median	P value
Sex				
Male	46	9.56 \pm 14.43	2.69	0.030^b
Female	14	3.79 \pm 8.56	0.76	
Smoke				
No	12	3.33 \pm 8.53	1.12	<0.001^c
Light	8	0.91 \pm 1.24	0.38	
Heavy	35	8.29 \pm 13.91	2.29	
Ex Heavy	5	16.74 \pm 12.85	17.51	
EtOH Consumption				
No	18	8.25 \pm 15.1	1.54	0.73 ^c
Social	32	6.43 \pm 11.72	1.77	
Heavy	10	6.70 \pm 9.90	2.77	
HPV Status				
Negative	5	6.58 \pm 13.27	0.76	0.42 ^b
Positive	5	19.15 \pm 23.04	1.79	
Nodal Status				
0	20	8.85 \pm 14.86	1.43	0.72 ^c
1	8	1.82 \pm 2.19	0.98	
2	31	7.38 \pm 12.22	1.93	
TNM Stage				
I	1			0.63 ^c
II	10	6.32 \pm 10.31	1.43	
III	7	6.39 \pm 10.78	2.60	
IV	42	7.45 \pm 13.36	1.87	
Primary Site				
Hypopharynx	8	4.34 \pm 3.35	3.78	0.19 ^d
Larynx	13	2.65 \pm 3.49	0.99	
Oral Cavity	26	7.32 \pm 13.86	1.09	
Oropharynx	13	12.44 \pm 16.6	3.65	

Histology				
High	18	8.69±14.63	1.77	
Intermediate	31	7.50±12.92	1.43	
Low Intermediate	2	1.61±1.36	1.62	0.41 ^c
Low	8	2.15±3.00	1.12	
Undifferentiated	1			
Disease Progression				
No	40	9.40±14.14	2.65	
Yes	20	2.25±5.44	0.77	0.006^b

^a Standard Deviation

^b Calculated using the "Mann Whitney test"

^c Calculated using the "Jonckheere–Terpstra test"

^d Calculated using the "Kruskal Wallis Test"